

# M Neil Reaume

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9988175/publications.pdf>

Version: 2024-02-01

45  
papers

1,714  
citations

706676

14  
h-index

371746

37  
g-index

45  
all docs

45  
docs citations

45  
times ranked

2742  
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over 837-846.	0.8	29
2	CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).. Journal of Clinical Oncology, 2022, 40, TPS4619-TPS4619.	0.8	2
3	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, LBA5004-LBA5004.	0.8	29
4	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Network Open, 2021, 4, e2021869.	2.8	104
5	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European Urology, 2021, 79, 334-338.	0.9	39
6	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer, 2021, 19, 521-530.	0.9	8
7	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) â€” an International mRCC Database Consortium (IMDC) analysis. Journal of Geriatric Oncology, 2021, 12, 820-826.	0.5	10
8	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	0.9	28
9	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. JAMA Oncology, 2020, 6, 1751.	3.4	20
10	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97.	0.3	11
11	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.. Journal of Clinical Oncology, 2020, 38, 5068-5068.	0.8	2
12	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5071-5071.	0.8	2
13	The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials.. Journal of Clinical Oncology, 2020, 38, e14099-e14099.	0.8	0
14	Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2020, 38, 633-633.	0.8	0
15	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 642-642.	0.8	9
16	Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2020, 38, 620-620.	0.8	1
17	Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.. Journal of Clinical Oncology, 2020, 38, 333-333.	0.8	10
18	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.	0.3	10

#	ARTICLE	IF	CITATIONS
19	The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. <i>Medical Oncology</i> , 2019, 36, 18.	1.2	6
20	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	13.9	982
21	Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOC 0521 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1159-1168.	0.8	112
22	Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4516-4516.	0.8	6
23	Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP) Tj ETQq1 1 0,784314 rgBT /Overall LBA2-LBA2.	0.8	6
24	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16501-e16501.	0.8	0
25	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018, 12, 173-80.	0.3	16
26	Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4505-4505.	0.8	6
27	Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 193-193.	0.8	2
28	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-667.	0.8	0
29	Application of Canadian hereditary renal cell carcinoma risk criteria to a population database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 621-621.	0.8	0
30	The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17005-e17005.	0.8	0
31	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017, 11, 112.	0.3	32
32	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017, 11, 310-320.	0.3	6
33	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017, 35, 468-468.	0.8	4
34	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16078-e16078.	0.8	0
35	Structured assessment and followup for patients with hereditary kidney tumour syndromes. <i>Canadian Urological Association Journal</i> , 2016, 10, 214.	0.3	12
36	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015, 9, 164.	0.3	18

#	ARTICLE	IF	CITATIONS
37	A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 457-465.	1.1	41
38	A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8046-8046.	0.8	2
39	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG Tj ETQq1 1 0.784314 rgBT /Over	0.8	14
40	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG Tj ETQq0 0 0 rgBT /Over	0.8	10
41	A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4573-TPS4573.	0.8	0
42	Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey. <i>Canadian Urological Association Journal</i> , 2014, 8, 832.	0.3	5
43	Acute Cardiogenic Shock Induced by Infusional 5-Fluorouracil. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-3.	0.2	9
44	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non-Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. <i>Clinical Lung Cancer</i> , 2014, 15, 52-57.	1.1	32
45	Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013, 7, 319.	0.3	30